Covid-19: Time for a paradigm change.
作者信息
Buonaguro Franco M, Ascierto Paolo A, Morse Gene D, Buonaguro Luigi, Puzanov Igor, Tornesello Maria Lina, Bréchot Christian, Gallo Robert C
机构信息
Istituto Nazionale Tumori-IRCCS "Fondazione G. Pascale", Naples, Italy.
Center for Integrated Global Biomedical Sciences, University at Buffalo, The State University of New York, USA.
出版信息
Rev Med Virol. 2020 Sep;30(5):e2134. doi: 10.1002/rmv.2134. Epub 2020 Jul 3.
Abstract
摘要
相似文献
1
Covid-19: Time for a paradigm change.新冠疫情：是时候进行范式转变了。
Rev Med Virol. 2020 Sep;30(5):e2134. doi: 10.1002/rmv.2134. Epub 2020 Jul 3.
2
Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.严重急性呼吸综合征冠状病毒 2 感染的免疫病理学和免疫治疗策略。
Rev Med Virol. 2020 Sep;30(5):e2123. doi: 10.1002/rmv.2123. Epub 2020 Jul 9.
3
Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.用雷帕霉素靶向T细胞衰老和细胞因子风暴以预防COVID-19的严重进展。
Clin Immunol. 2020 Jul;216:108464. doi: 10.1016/j.clim.2020.108464. Epub 2020 May 13.
4
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.罗沙司他抑制细胞因子信号转导及其在 COVID-19 治疗中的意义。
Clin Immunol. 2020 Sep;218:108517. doi: 10.1016/j.clim.2020.108517. Epub 2020 Jun 23.
5
Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.新型冠状病毒感染中肠道和肺部的免疫协调。
Virus Res. 2020 Sep;286:198103. doi: 10.1016/j.virusres.2020.198103. Epub 2020 Jul 24.
6
Overview of lethal human coronaviruses.致死性人类冠状病毒概述。
Signal Transduct Target Ther. 2020 Jun 10;5(1):89. doi: 10.1038/s41392-020-0190-2.
7
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.COVID-19 中的免疫反应：通过靶向 SARS-CoV-2 触发的途径来应对药理学挑战。
Signal Transduct Target Ther. 2020 May 29;5(1):84. doi: 10.1038/s41392-020-0191-1.
8
COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.新型冠状病毒肺炎、肺肥大细胞、细胞因子风暴以及木犀草素的有益作用
Biofactors. 2020 May;46(3):306-308. doi: 10.1002/biof.1633. Epub 2020 Apr 27.
9
Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.重症新型冠状病毒肺炎、内稳态与有效糖皮质激素治疗的“意外”效果
Clin Immunol. 2020 Oct;219:108550. doi: 10.1016/j.clim.2020.108550. Epub 2020 Jul 31.
10
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.新型冠状病毒肺炎的新兴治疗方法：包括药物过敏在内的药物不良反应。
J Allergy Clin Immunol. 2020 Oct;146(4):786-789. doi: 10.1016/j.jaci.2020.07.008. Epub 2020 Jul 22.
引用本文的文献
1
Longitudinal Follow-Up of Serum and Urine Biomarkers Indicative of COVID-19-Associated Acute Kidney Injury: Diagnostic and Prognostic Impacts.血清和尿液生物标志物对 COVID-19 相关性急性肾损伤的纵向随访：诊断和预后影响。
Int J Mol Sci. 2023 Nov 18;24(22):16495. doi: 10.3390/ijms242216495.
2
Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.无症状和有症状的儿科及成年患者中 SARS-CoV-2 表位的免疫特征分析。
J Transl Med. 2023 Feb 14;21(1):123. doi: 10.1186/s12967-023-03963-5.
3
Highly pathogenic coronaviruses and the kidney.高致病性冠状病毒与肾脏。
Biomed Pharmacother. 2022 Dec;156:113807. doi: 10.1016/j.biopha.2022.113807. Epub 2022 Oct 11.
4
SARS-CoV-2 Omicron and its current known unknowns: A narrative review.SARS-CoV-2 奥密克戎及其当前已知的未知：叙述性综述。
Rev Med Virol. 2023 Jan;33(1):e2398. doi: 10.1002/rmv.2398. Epub 2022 Sep 23.
5
Correlations between Kidney and Heart Function Bioindicators and the Expressions of Toll-Like, ACE2, and NRP-1 Receptors in COVID-19.新冠病毒病中肾脏与心脏功能生物标志物及Toll样受体、血管紧张素转换酶2和神经纤毛蛋白-1受体表达之间的相关性
Vaccines (Basel). 2022 Jul 11;10(7):1106. doi: 10.3390/vaccines10071106.
6
The Associations between Cytokine Levels, Kidney and Heart Function Biomarkers, and Expression Levels of Angiotensin-Converting Enzyme-2 and Neuropilin-1 in COVID-19 Patients.新冠病毒肺炎患者细胞因子水平、肾脏和心脏功能生物标志物以及血管紧张素转换酶2和神经纤毛蛋白1表达水平之间的关联
Vaccines (Basel). 2022 Jun 29;10(7):1045. doi: 10.3390/vaccines10071045.
7
CRISPR-Cas System: A Promising Diagnostic Tool for Covid-19.CRISPR-Cas系统：一种用于新冠病毒的有前景的诊断工具。
Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):3-9. doi: 10.18502/ajmb.v14i1.8165.
8
Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction.挺过风暴：SARS-CoV-2严重程度预测中的细胞因子生物标志物
Vaccines (Basel). 2022 Apr 14;10(4):614. doi: 10.3390/vaccines10040614.
9
Omicron - The new SARS-CoV-2 challenge?奥密克戎——新的 SARS-CoV-2 挑战？
Rev Med Virol. 2022 Jul;32(4):e2358. doi: 10.1002/rmv.2358. Epub 2022 Apr 21.
10
Novel insights into NOD-like receptors in renal diseases.新型 NOD 样受体在肾脏疾病中的研究进展。
Acta Pharmacol Sin. 2022 Nov;43(11):2789-2806. doi: 10.1038/s41401-022-00886-7. Epub 2022 Apr 1.
本文引用的文献
1
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin.糖皮质激素联合人免疫球蛋白治疗冠状病毒暴发性心肌炎
Eur Heart J. 2021 Jan 7;42(2):206. doi: 10.1093/eurheartj/ehaa190.
2
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
3
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.比较嵌合抗原受体T细胞毒性分级系统：美国血液与骨髓移植学会（ASTCT）分级系统的应用及管理意义
Blood Adv. 2020 Feb 25;4(4):676-686. doi: 10.1182/bloodadvances.2019000952.
4
The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis.糖皮质激素对流感病毒性肺炎患者病死率的影响：系统评价和荟萃分析。
Crit Care. 2019 Mar 27;23(1):99. doi: 10.1186/s13054-019-2395-8.
5
Direct-acting antiviral treatment for hepatitis C.丙型肝炎的直接抗病毒治疗
Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11.
6
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.托珠单抗对白细胞介素 6 受体的抑制作用可减轻非 ST 段抬高型心肌梗死中 C5a 受体 1 和 2 的表达。
Front Immunol. 2018 Sep 12;9:2035. doi: 10.3389/fimmu.2018.02035. eCollection 2018.
7
Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.21世纪的过敏反应：表型、内型和生物标志物。
J Asthma Allergy. 2018 Jun 20;11:121-142. doi: 10.2147/JAA.S159411. eCollection 2018.
8
Cytokine release syndrome.细胞因子释放综合征。
J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9.
9
The role of C5a in acute lung injury induced by highly pathogenic viral infections.C5a在高致病性病毒感染所致急性肺损伤中的作用。
Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28. Epub 2015 May 6.
10
Recent developments in anti-herpesvirus drugs.抗疱疹病毒药物的最新进展。
Br Med Bull. 2013;106:213-49. doi: 10.1093/bmb/ldt011. Epub 2013 Apr 17.
Zotero 插件